In a new publication from Cardiovascular Innovations and Applications; DOI https:/
In-stent thrombosis (IST) is a rare yet dangerous complication that may occur despite optimized coronary intervention in the cardiac catheterization laboratory. The authors report a case of an 81-year-old man who presented with ST-elevation myocardial infarction. Right coronary artery (RCA) occlusion was suspected. RCA angiography and percutaneous coronary intervention were performed. Complicated left coronary artery disease was subsequently discovered. Per cardiothoracic surgeon request, the patient was transitioned from ticagrelor to clopidogrel therapy in preparation for coronary artery bypass grafting. The patient experienced IST the day before surgery while receiving clopidogrel.
The authors review this case, which highlights the complexity of antiplatelet therapy choice and the role of genetic testing in evaluation of IST risk.
Citation information: In-Stent Thrombosis after Antiplatelet Therapy Conversion while Awaiting Coronary Bypass, Nathan Burke, Tawanna Charlton, Hussam Hawamdeh, and Ki Park, Cardiovasc. Innov. App., 2020, https:/
Keywords: Acute myocardial infarction/ST-elevation myocardial infarction; antiplatelet therapy; genetics; platelet biology; drug-eluting stent; drugs/pharmacotherapy
CVIA is available on the IngentaConnect platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. CVIA is indexed in the EMBASE, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.